International Hepatology Archives - Page 38 of 47

Potentially Underestimated! Recent Advances in Screening, Treatment, and Prevention of HBV Combined with HDV Infection

By Mourabit Halima 2024.01.12

Hepatitis D virus (HDV) is a defective virus that relies on hepatitis B virus (HBV) to produce infectious particles for transmission. The combined infection of both is considered one of the most severe forms of chronic viral hepatitis, posing a significant threat to human health. At the 9th "Silk Road Hepatitis Forum," Dr. Xiaozhong Wang, Director of the Hepatology Department at the Xinjiang Uyghur Autonomous Region Traditional Chinese Medicine Hospital, was invited to present the latest research developments in screening, treatment, and prevention of HBV combined with HDV infection, providing essential insights for clinical management. "International Digest" has invited Dr. Xiaozhong Wang and Dr. Liu Yunxiao to share the highlights of the report.

Unresolved Issues in Pediatric Hepatitis B Treatment Guidelines

By Mourabit Halima 2024.01.12

China is a high-incidence country for hepatitis B virus (HBV), with mother-to-child transmission being a significant route of HBV infection in children. If infected with HBV, 15% to 25% of children may develop into chronic carriers, posing risks of liver cirrhosis and liver cancer. Therefore, understanding the epidemiological characteristics of the disease and taking timely and effective treatment measures are of great practical significance. From November 17-19, 2023, the "15th Chronic Viral Hepatitis Antiviral Treatment Challenges and Hot Topics Academic Conference" was grandly held in Chongqing. It was hosted by the Chinese Medical Journal Company Ltd., organized by the Editorial Office of the Chinese Journal of Hepatology, and co-organized by the Hepatitis Group of the Chinese Society of Hepatology, the Second Affiliated Hospital of Chongqing Medical University, and the Chongqing Medical University Institute of Viral Hepatitis. At the conference, Dr. Junliang Fu of the Fifth Medical Center of the Chinese People's Liberation Army General Hospital sparked intense interest with his thematic discussion on hot issues in pediatric HBV clinical treatment. We are honored to have Dr. Junliang Fu for an in-depth interview, the contents of which are compiled here for our readers.

Discovery and Verification of HBV Auxiliary Receptor NRP1

By Lisa Cui 2024.01.11

Hepatitis B Virus (HBV) infection is one of the main causes of liver diseases, affecting approximately 292 million people worldwide who are chronic carriers of HBV, leading to severe conditions like liver cirrhosis and primary liver cancer. The infection process of HBV relies on the binding of the viral envelope proteins to receptors on the cell surface. Therefore, interfering with the binding of the viral envelope proteins and receptors can be an effective antiviral strategy. During the 15th Chronic Viral Hepatitis Antiviral Treatment Challenges and Hot Topics Academic Conference, held in Chongqing from November 17-19, 2023, and organized by the Chinese Medical Journal Company Ltd., Editorial Office of the Chinese Journal of Hepatology, and co-organized by the Hepatitis Group of the Chinese Society of Hepatology, the Second Affiliated Hospital of Chongqing Medical University, and the Chongqing Medical University Institute of Viral Hepatitis, Dr. Ailong Huang, President of Chongqing Medical University, shared his team's latest research findings on how HBV depends on various receptors and auxiliary receptors to infect cells. This research provides new insights into the mechanism of HBV invasion and the development of novel drugs to block HBV infection.

The Safety of Anticoagulation Therapy in Liver Cirrhosis Portal Vein Thrombosis and Its Impact on Hospital Outcomes.

By Mourabit Halima 2024.01.11

"The Hepatology Digest -Liver Vascular Disease Column" is an academic section jointly initiated by Dr. Xingshun Qi of the Department of Gastroenterology, Northern Theater General Hospital, at the invitation of the Hepatology Digest editorial team. It regularly collects and discusses the latest research in the field of liver vascular diseases. Every two weeks, on Wednesdays, it features an in-depth discussion of a significant publication, aiming to enlighten readers about the rationale behind these findings and inspire clinical research and practical application.

The Treatment and Clinical Cure of Childhood Hepatitis B

By Mourabit Halima 2024.01.10

China is a country with a high incidence of hepatitis B, and mother-to-child transmission is an important route for children in China to contract the hepatitis B virus (HBV). Although chronic HBV infection in childhood rarely progresses to active hepatitis, there is still a risk of developing cirrhosis and liver cancer. Therefore, understanding the epidemiological characteristics of childhood hepatitis B and taking effective prevention and control measures are particularly important to reduce the incidence of childhood hepatitis B in China and promote healthy growth. In recent years, as the goal of clinical cure for hepatitis B has gradually gained more attention, the issue of clinical cure for childhood hepatitis B has also received increasing focus. At the recently concluded "15th Academic Conference on Antiviral Therapy Difficulties and Hotspots in Chronic Viral Hepatitis," Dr. Fusheng Wang from the Fifth Medical Center of the PLA General Hospital presented a special report on "Treatment and Clinical Cure of Childhood Hepatitis B," offering an in-depth analysis of these issues.

CDL (co-management of diabetes-liver diseases strategy,) Literature Monthly Review – November 2023, Issue 10

By Lisa Cui 2024.01.10

Diabetes and liver diseases are common chronic conditions in China, and they interact in terms of pathogenesis, clinical manifestations, and therapeutic targets, often posing mutual risk factors. Co-management of these conditions is beneficial for reducing the burden of disease. To support the development of diabetes and liver disease co-management in China, this publication Hepatology Digest, in collaboration with the co-management of diabetes-liver diseases strategy, (CDL), presents the CDL Literature Monthly Review column. Each month, we share research literature related to the mechanisms and therapeutic advances in diabetes combined with liver diseases. We invite experts in the field to comment on the literature, hoping to provide insights and assistance for professionals, researchers, and frontline medical workers engaged in scientific research and clinical diagnosis and treatment.

CDM Monthly Review (November 2023, Issue 75)

By Mourabit Halima 2024.01.10

Hello experts and colleagues, in this 75th issue of the CDM Monthly Review for November 2023, we share six recent publications in the field of portal hypertension diagnosis and treatment (three on diagnosis and monitoring, and three on multidisciplinary treatment). This issue features guest experts: Dr. Bingtian Dong from the Department of Ultrasound at the First Affiliated Hospital of Anhui Medical University, Dr.Ningning Wang from the Department of Gastroenterology at the First Affiliated Hospital of China Medical University, Dr.Lei Zheng from the Department of General Surgery at the Ninth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine, and Dr. Sheng Wang from the Department of Gastroenterology at the Third Affiliated Hospital of Sun Yat-sen University.

Application of Ultrasound Elastography Scoring in Diagnosing Potential Porto-Sinusoidal Vascular Disease in Patients with Portal Vein Thrombosis

By Mourabit Halima 2024.01.09

The "Hepatology Digest-Vascular Liver Disease Column" is an academic column jointly initiated by Dr. Xingshun Qi of the Department of Gastroenterology, Northern Theater Command General Hospital, at the invitation of the editorial department of " Hepatology Digest". This column regularly collects and organizes research progress in the field of vascular liver disease. Every two weeks (on Wednesday), an important piece of literature is selected for in-depth discussion. The aim is to help readers understand the rationale behind these advancements and to inspire clinical and scientific thinking, putting knowledge into practice.

From “Clinical Cure” to “Disease Cure” – The Long-term Treatment of Chronic Hepatitis B

By Lisa Cui 2024.01.09

From November 17-19, 2023, the "15th Chronic Viral Hepatitis Antiviral Treatment Difficulties and Hotspots Academic Conference" was grandly held in Chongqing. Sponsored by the Chinese Medical Journal Co., Ltd., organized by the Editorial Department of the Chinese Journal of Hepatology, and co-organized by the Hepatitis Group of the Chinese Society of Hepatology of the Chinese Medical Association (CMA), the Second Affiliated Hospital of Chongqing Medical University, and the Viral Hepatitis Research Institute of Chongqing Medical University, the conference focused on chronic viral hepatitis treatment and high-quality development of the discipline, providing a platform for information exchange and interaction among frontline clinicians and clinical researchers. Dr. Xiaoguang Dou from Shengjing Hospital of China Medical University, the chairman of the conference, shared the highlights and engaged in an in-depth interview on the hot topic of chronic hepatitis B clinical treatment. The content is organized for the readers' benefit.

Construction and Validation of a Hepatocellular Carcinoma Prognosis Model Based on Stress Granules

By Mourabit Halima 2024.01.08

In an effort to keep clinicians and researchers in the field of hepatology abreast of the latest academic knowledge and research trends, " Hepatology Digest " has collaborated with the "Journal of Clinical and Translational Hepatology" (JCTH) to introduce the "Journal Co-Read" section. Each week, this section selects and interprets highlights from a key publication, summarizing its main points in the hope of enhancing clinical diagnostic and treatment levels, inspiring research thinking, and improving writing skills.